这些研究发现支持了RAD51测试在调整早期乳腺癌患者疗法策略上的潜力，未来的生物标志物的驱动研究（比如RADIOLA研究）就旨在验证RAD51在晚期乳腺癌中的作用，其结果预计将会在今年晚些时候公布，而研究人员应该考虑利用目前的数据来完善分层因素并改善 ...

The PATHWAY HER2 (4B5) test is now FDA-approved to assess HER2-ultralow status in metastatic breast cancer, expanding its ...

Patients whose metastatic colorectal cancer has progressed following chemotherapy and who lack mutations in the RAS and BRAF ...

Roche’s PATHWAY HER2 (4B5) test helps identify patients with HER2-ultralow breast cancer, who may be eligible for targeted ...

During a Case-Based Roundtable event, Laura Huppert, MD, discussed data and considerations around using T-DXd in breast ...

引言恩美曲妥珠单抗（T-DM1）是全球首个获批上市的乳腺癌抗体偶联药物（ADC）。2018 年，发表于 New England Journal of Medicine 的 Ⅲ 期开放标签试验 KATHERINE ...

The FDA has approved an expanded label for Roche’s PATHWAY anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody test, which ...

Roche has secured a new FDA approval for its first companion diagnostic test aimed at identifying breast cancer patients with ...

【导读】激素受体阳性（HR+）/人表皮生长因子受体2阴性（HER2-）乳腺癌是最常见的乳腺癌类型，持续复发仍是一个重要的临床问题。目前针对HR+/HER2-乳腺癌患者的复发预测模型仍存在局限性。整合多维数据是预测复发的一种有前途的替代方法。2025年 ...

The researchers found that imlunestrant prolonged progression-free survival (PFS) when compared to standard care in patients with ESR1 mutations, but there was no PFS benefit observed in the overall ...

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

Enhertu first secured approval in 2019 for patients with high levels of HER2, a protein that promotes cancer cell growth. In ...